|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma.
|
31093278 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The genetic duet of BRAF V600E/RAS and TERT promoter mutations is a most robust prognostic genetic pattern for poor prognosis of differentiated thyroid cancer.
|
30717896 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results show a high rate and a strong prognostic role of the classical BRAF (V600E) mutation and also suggest a common occurrence of non-hot spot mutations in adult DTC from this highly inbred population.
|
27387551 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data suggest that BRAF(V600E)-mutated DTCs are significantly more (18)F-FDG-avid than BRAF-WT tumors.
|
25814520 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Neither the presence of V600E BRAF mutations nor that of a well-differentiated thyroid carcinoma changed the outcome or disease-free survival.
|
24777145 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study investigated the role of molecular studies in preoperative diagnosis of DTC and</span> the association of p.V600E mutation with prognostic factors.
|
24468978 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7.0% (9/129) of thyroid nodules of differentiated thyroid cancer, representing a 100% diagnostic specificity and 7.0% sensitivity, with the latter rising to 38.0% (49/129) when combined with BRAF V600E testing.
|
25121551 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The aims of this study were to evaluate the utility of US-guided FNAB in the diagnostic assessment of nodules with or without clinical/US features suggestive for malignancy and to investigate the additional contribution of BRAF V600E mutation analysis in the detection of differentiated thyroid cancer.
|
22535974 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).
|
19356676 |
2009 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
DTC was present in half of the cases.BRAF V600E mutation was identified in nine of 36 (25%) ATCs; seven cases had identical mutations in both the ATC and DTC components.
|
17989125 |
2008 |